VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary FibrosisGlobeNewsWire • 04/19/23
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201GlobeNewsWire • 03/30/23
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual ConferenceGlobeNewsWire • 03/22/23
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/09/23
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care ConferenceGlobeNewsWire • 02/22/23
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201GlobeNewsWire • 02/15/23
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201GlobeNewsWire • 01/09/23
VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access EventGlobeNewsWire • 12/12/22
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor PlatformGlobeNewsWire • 12/07/22
VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech ConferenceGlobeNewsWire • 12/02/22
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/18/22
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of VitiligoGlobeNewsWire • 11/17/22
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/22
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/22
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to BuyZacks Investment Research • 08/17/22
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/12/22
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic DermatitisGlobeNewsWire • 08/10/22
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development ConferenceGlobeNewsWire • 07/19/22
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic DermatitisGlobeNewsWire • 06/17/22
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment ConferenceGlobeNewsWire • 05/18/22